Mtruong34, It certainly feels to me that you ar
Post# of 154017
(Total Views: 745)
Posted On: 01/07/2021 6:37:33 AM
Mtruong34,
It certainly feels to me that you are criticizing Cytodyn selecting wrong endpoints. Again, as has been discussed recurrently, endpoints were chosen very early in the pandemic and in conjunction with the FDA.
Yet you wrote:
“ Well where were these scientists when they selected an inferior CD10 PE and included patients with symptom scores less than 4? It was completely pertinent in light of the CD10 total symptom score PE being subjective versus NEWS2 SE being more objective.
Read More: https://investorshangout.com/post/view?id=601...z6irPTJDfd
Again, phase 2 are not registrational trials. Were it the case that the FDA had desired an effective treatment for mild/moderate patients after CD10 results(I certainly don’t believe Remdesivir qualifies), Cytodyn would have conducted a phase 3 in M/M with NEWS2 as primary endpoint.
We continue on with CD12, NP will always be an occasionally cranky advocate for Cytodyn (and us), and Vyrologix/leronlimab will soon emerge from the shadows.
I expect with the more complete understanding of Covid and immune dysfunction, that the long haulers trial endpoints will be appropriately selected.
GLTU/A
It certainly feels to me that you are criticizing Cytodyn selecting wrong endpoints. Again, as has been discussed recurrently, endpoints were chosen very early in the pandemic and in conjunction with the FDA.
Yet you wrote:
“ Well where were these scientists when they selected an inferior CD10 PE and included patients with symptom scores less than 4? It was completely pertinent in light of the CD10 total symptom score PE being subjective versus NEWS2 SE being more objective.
Read More: https://investorshangout.com/post/view?id=601...z6irPTJDfd
Again, phase 2 are not registrational trials. Were it the case that the FDA had desired an effective treatment for mild/moderate patients after CD10 results(I certainly don’t believe Remdesivir qualifies), Cytodyn would have conducted a phase 3 in M/M with NEWS2 as primary endpoint.
We continue on with CD12, NP will always be an occasionally cranky advocate for Cytodyn (and us), and Vyrologix/leronlimab will soon emerge from the shadows.
I expect with the more complete understanding of Covid and immune dysfunction, that the long haulers trial endpoints will be appropriately selected.
GLTU/A
(7)
(0)